Efficacy of the combination therapy with dendritic cells and cytokine-induced killer cells in the treatment of advanced colorectal cancer
Zheng Jie;Jiang Longwei;Yao Lu;Ai Yueqin;Zhang Yan;Huang Weiqian;Gao Yanrong;Zhang Chuang;Zhao Hua;Hu Jianhua;Jia Shaochang;Yu Shuyong;Department of Tumor Biotherapy,No.81 Hospital of PLA;Oncology Department,No.187 Hospital of PLA;
Objective: To evaluate the safety and efficacy of combination therapy with dendritic cells( DCs) and cytokine- induced killer( CIK) cells in the treatment of advanced colorectal cancer( CRC). Methods: Peripheral blood mononuclear cells( PBMCs) were collected from 142 patients with stage Ⅲ ~ Ⅳ CRC who were admitted to the Tumor Biotherapy Center of the No. 81 Hospital of PLA in Nanjing from August,2011 to December,2014. The cells were cultured ex vivo to generate DC and CIK cells. After sensitized with cell lysates from colon cancer cells Colo-320 or rectal cancer cells HCT-116,the DCs were transfused to CRC patients after combined with the CIK cells. T-lymphocyte subsets,serum CEA level,and clinical features were evaluated before and after the combined DC and CIK treatment. Results: Following the combined DC and CIK immunotherapy in patients with advanced CRC for 40 months,the overall response rate was16. 2%,the disease control rate was 60. 0%,one- year overall survival rate was 47%,and both two-year and three-year overall survival rate was maintained at 31%. No significant alterations in T-lymphocyte subsets,CD4+/ CD8+ratio,and CEA level were found in these patients after the combination therapy. Single-factor analysis indicated that tumor stage( P = 0. 015),the frequency of immunotherapy( P = 0. 037),and CEA value( P = 0. 037) affected significantly the survival period of these CRC patients. Multivariate Cox model indicated that frequency of the combined DC and CIK immunotherapy( P = 0. 024) and age( P = 0. 015) associated significantly with the risk of cancer-related death in these CRC patients. Conclusion: The combined autologous DC / CIK immunotherapy is a safe and feasible therapeutic approach and it may improve the long- term survival rate in patients with stage Ⅲ ~ Ⅳ CRC.